Show simple item record

dc.contributor.authorSpratley, Samanthaen
dc.contributor.authorDeane, Janeten
dc.date.accessioned2016-05-03T11:01:08Z
dc.date.available2016-05-03T11:01:08Z
dc.date.issued2016en
dc.identifier.citationSpratley & Deane. Journal of Neuroscience Research (2016)en
dc.identifier.issn0360-4012
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/255836
dc.description.abstractMissense mutations in the lysosomal hydrolase β-galactocerebrosidase (GALC) account for at least 40% of known cases of Krabbe disease (KD). The majority of these missense mutations are predicted to disrupt the fold of the enzyme, preventing sufficient amounts of GALC from reaching its site of action in the lysosome. The predominant central nervous system pathology and absence of accumulated primary substrate within the lysosome mean that strategies used to treat other lysosomal storage disorders (LSDs) are insufficient in KD, highlighting the still unmet clinical need for successful KD therapeutics. Pharmacological chaperone therapy (PCT) is one strategy being explored to overcome defects in GALC caused by missense mutations. To date, a number of small molecule inhibitors have been identified as promising chaperone candidates for GALC. Here we review and discuss the new insights gained from these studies and highlight the importance of characterizing both the chaperone interaction and the underlying mutation in order to properly define a responsive population and to improve the translation of existing lead molecules into successful KD therapeutics. We also highlight the need to use multiple complementary methods to monitor PCT effectiveness. Finally, we explore the exciting potential of using combination therapy to ameliorate disease through the use of PCT with existing therapies or with more generalized therapeutics such as proteasomal inhibition, which have been shown to have synergistic effects in other LSDs. This, alongside advances in CNS delivery of recombinant enzyme and targeted rational drug design provides a promising outlook for the development of KD therapeutics.
dc.description.sponsorshipS.J.S. is funded by an MRC PhD studentship and J.E.D. is supported by a Royal Society University Research Fellowship (UF100371). The Cambridge Institute for Medical Research is supported by Wellcome Trust Strategic Award 100140.
dc.languageEnglishen
dc.language.isoenen
dc.publisherWiley
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectKrabbe diseaseen
dc.subjectpharmacological chaperone therapyen
dc.subjectβ-galactocerebrosidase (GALC)en
dc.subjectlysosomal storage disorderen
dc.subjectgalactocerebrosideen
dc.titleNew therapeutic approaches for Krabbe disease: the potential of pharmacological chaperonesen
dc.typeArticle
dc.description.versionThis is the author accepted manuscript. It is currently under an indefinite embargo pending publication by Wiley.en
prism.publicationDate2016en
prism.publicationNameJournal of Neuroscience Researchen
dc.rioxxterms.funderWellcome Trust
dc.rioxxterms.projectid100140
dcterms.dateAccepted2016-04-18en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2016en
dc.contributor.orcidDeane, Janet [0000-0002-4863-0330]
dc.identifier.eissn1097-4547
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idRoyal Society (1562)
pubs.funder-project-idRoyal Society (uf100371)
pubs.funder-project-idWellcome Trust (100140/Z/12/Z)
cam.orpheus.successThu Jan 30 12:54:21 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International